aTyr Pharma's Phase 3 Sarcoidosis Drug Misses Primary Endpoint

September 15, 2025

•

1 min read

•

Stock Titan

Phase 3 EFZO-FIT trial missed steroid reduction goal but showed 52.6% complete steroid withdrawal and improved lung scores. Drug well-tolerated, company plans FDA discussions for path forward.

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis 09/15/2025 - 07:30 AM Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, alth... [12516 chars]

Read Original Article

Source: Stock Titan

Visit Source

Share this article

Twitter Facebook

Back to business news